See the DrugPatentWatch profile for Jornay
Jornay PM is a prescription medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in individuals aged 6 and older [1]. It is designed to be taken in the evening and its extended-release formulation delivers a dose of medication upon waking and a second dose later in the day [2].
What makes Jornay PM different from other ADHD medications?
Jornay PM utilizes a unique, dual-pulse extended-release technology. This means the medication is released in two distinct phases. The first dose is released when the patient wakes up, and the second dose is released approximately 8-10 hours later. This delivery system aims to provide symptom control throughout the day, from morning to evening [1][2].
How does Jornay PM work?
Jornay PM contains the active ingredient methylphenidate. Methylphenidate is a central nervous system stimulant that works by increasing the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine. These neurotransmitters play a role in regulating attention, impulse control, and hyperactivity [1][3].
When does Jornay PM's patent protection end?
Patent information for specific medications can be complex and is subject to change. To find the most up-to-date details on patent expiry for Jornay PM (methylphenidate hydrochloride extended-release), consulting resources like DrugPatentWatch.com is recommended [4]. These sites track patent filings, grants, and expiration dates, which are crucial for understanding when generic versions might become available.
What are the potential side effects of Jornay PM?
Common side effects associated with Jornay PM include decreased appetite, insomnia, anxiety, irritability, headache, and nausea [1]. Serious side effects can include cardiovascular problems, psychiatric disorders, and circulation problems in the fingers and toes [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Who manufactures Jornay PM?
Jornay PM is manufactured by Ironshore Pharmaceuticals [1].
How does Jornay PM compare to other methylphenidate medications?
While Jornay PM and other methylphenidate medications share the same active ingredient, their delivery systems differ. Traditional extended-release methylphenidate formulations typically release medication gradually over a longer period. Jornay PM's dual-pulse system is designed to provide a more targeted release profile, with a significant release upon waking and another later in the day. This can affect the duration and pattern of symptom control [2].
What is the cost of Jornay PM?
The cost of Jornay PM can vary depending on insurance coverage, pharmacy, and dosage. Patients often explore options like manufacturer coupons or patient assistance programs to help manage the expense [5].
Are there alternatives to Jornay PM for ADHD treatment?
Yes, there are several alternative treatments for ADHD. These include other stimulant medications (e.g., Adderall, Vyvanse), non-stimulant medications (e.g., Strattera, Intuniv), and behavioral therapies. The choice of treatment depends on individual patient needs, response to medication, and medical history [3][6].
*
**Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK560577/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988605/
[3] https://www.additudemag.com/adhd-medication-list-stimulant-non-stimulant/
[4] https://drugpatentwatch.com/
[5] https://www.goodrx.com/jornay-pm
[6] https://www.mayoclinic.org/diseases-conditions/adult-adhd/diagnosis-treatment/drc-20350851